Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA – Get Free Report) shares dropped 0.5% on Wednesday. The company traded as low as $1.52 and last traded at $1.57. 18,806 shares were traded during trading, a decline of 50% from the average daily volume of 37,397 shares. The stock had previously closed at $1.5780.
Wall Street Analysts Forecast Growth
A number of equities analysts recently issued reports on the company. UBS Group reissued a “buy” rating on shares of Innate Pharma in a report on Tuesday, August 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Innate Pharma in a research report on Tuesday, September 22nd. BTIG Research reaffirmed a “buy” rating and set a $9.00 target price on shares of Innate Pharma in a research note on Thursday, September 17th. Citigroup upgraded Innate Pharma from a “buy” rating to an “outperform” rating in a research report on Tuesday, August 11th. Finally, HC Wainwright reissued a “buy” rating on shares of Innate Pharma in a research note on Monday, September 21st. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $6.67.
View Our Latest Stock Analysis on IPHA
Innate Pharma Price Performance
The company’s 50-day moving average is $1.84 and its 200 day moving average is $1.78.
Innate Pharma Company Profile
Innate Pharma SA is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s research is centered on the innate immune system, including natural killer cells and other immune cells that can recognize and attack tumors. Its product candidates include monoclonal antibodies, immune-cell engagers and other treatments designed to stimulate or direct immune responses against cancer.
Innate Pharma’s pipeline has included lacutamab, an antibody targeting KIR3DL2 for the treatment of certain T-cell lymphomas, including cutaneous T-cell lymphoma.
Further Reading
- Five stocks we like better than Innate Pharma
- Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating Costs
- Lockheed Martin’s Record $292 Billion Backlog Comes With a Delivery Test
- Palantir’s Next Big Test Isn’t a Partnership—It’s the Numbers
- Kinder Morgan’s $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings Beat
Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
